• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sema4 Holdings Corp.

    6/6/23 4:51:32 PM ET
    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $SMFR alert in real time by email
    DEFA14A 1 defa14a-662022.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No. )
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material under §240.14a-12
    genedxlogoa.jpg
    GENEDX HOLDINGS CORP.
    (Name of Registrant as Specified in Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check the appropriate box):
    ☒No fee required.
    ☐Fee paid previously with preliminary materials.
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.





    GeneDx Holdings Corp.

    Supplement to the Proxy Statement for the Annual Meeting of Shareholders to be held on June 14, 2023

    This proxy statement supplement (this “Proxy Supplement”) supplements, updates and amends the definitive proxy statement of GeneDx Holdings Corp. (the “Company”) filed with the Securities and Exchange Commission on April 28, 2023 (the “Proxy Statement”) regarding the annual meeting of shareholders to be held on June 14, 2023 (the “Annual Meeting”) at 9:00 a.m. Eastern time.

    This Proxy Supplement contains important supplemental information to the Proxy Statement and should be read in conjunction with the Proxy Statement. To the extent that information in this Proxy Supplement differs from, conflicts with, or updates information contained in the Proxy Statement, the information in this Proxy Supplement is more current and shall prevail. The Company is providing you with the following additional information in order to further assist you in voting your shares at the Annual Meeting.

    Annual Meeting to be Held Through a “Hybrid” Model: In Person and Online
    In addition to holding the Annual Meeting in person at the Company’s corporate headquarters at 333 Ludlow Street, North Tower, Stamford, Connecticut 06902, the Company has determined to make the Annual Meeting also accessible via live audio webcast at www.virtualshareholdermeeting.com/WGS2023 for participants, with detailed attendance methods as outlined below. Even if you are planning on attending the Annual Meeting in person or online, please promptly submit your proxy vote via the Internet, or, if you received a printed form of proxy in the mail, by completing, dating, signing and returning the proxy, so your shares will be represented at the Annual Meeting.
    Attending the Annual Meeting Online
    •Stockholder of Record: Shares Registered in Your Name. If your shares are registered in your name with Continental Stock Transfer & Trust Company and you wish to attend the Annual Meeting online via webcast, go to www.virtualshareholdermeeting.com/WGS2023 and enter the 16-digit control number included on your proxy card or notice of the meeting.

    •Beneficial Owner: Shares Registered in the Name of a Broker or Nominee. Beneficial owners will receive an email prior to the meeting with a link and instructions, including a 16-digit meeting control number, for accessing the Annual Meeting online. Beneficial owners should contact their bank or broker where their shares are held at least five (5) business days prior to the meeting date in order to ensure access.
    Login Time for Annual Meeting Webcast
    You can log in to the Annual Meeting webcast 15 minutes prior to the start of the meeting. If you encounter any difficulties accessing the Annual Meeting webcast during the check-in or meeting time, please call the technical support number that will be posted on the Virtual Shareholder Meeting login page (www.virtualshareholdermeeting.com/WGS2023) on the day of the meeting.

    Get the next $SMFR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMFR

    DatePrice TargetRatingAnalyst
    12/7/2022$3.00 → $1.00Buy → Neutral
    Goldman
    8/16/2022$4.00 → $2.00Buy → Hold
    Jefferies
    6/2/2022$3.50Buy
    Goldman
    11/19/2021$12.00Buy
    Goldman Sachs
    10/8/2021$12.00Buy
    BTIG Research
    9/30/2021$13.00Outperform
    Cowen & Co.
    9/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $SMFR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sema4 Holdings Corp downgraded by Goldman with a new price target

      Goldman downgraded Sema4 Holdings Corp from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      12/7/22 8:08:36 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Holdings Corp downgraded by Jefferies with a new price target

      Jefferies downgraded Sema4 Holdings Corp from Buy to Hold and set a new price target of $2.00 from $4.00 previously

      8/16/22 7:58:53 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Goldman resumed coverage on Sema4 Holdings Corp with a new price target

      Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50

      6/2/22 7:21:25 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Financials

    Live finance-specific insights

    See more
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

      Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity

      11/14/22 8:02:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

      STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast

      11/4/22 4:05:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Sema4 Holdings Corp.

      SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)

      2/9/24 7:10:06 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/17/23 4:15:23 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13G/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

      6/9/23 4:15:22 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

      STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming

      12/30/22 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

      STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai

      12/5/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ryan Jason bought $161,368 worth of shares (114,742 units at $1.41) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/20/23 4:32:17 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Pfenniger Richard C Jr bought $14,889 worth of shares (10,000 units at $1.49), increasing direct ownership by 92% to 20,918 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/8/23 7:19:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    SEC Filings

    See more
    • Sema4 Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GeneDx Holdings Corp. (0001818331) (Filer)

      1/8/24 8:58:39 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by Sema4 Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      11/15/23 5:17:42 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 10-Q filed by Sema4 Holdings Corp.

      10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

      11/3/23 4:06:35 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Saad Kareem sold $625 worth of shares (193 units at $3.24) and converted options into 546 shares, increasing direct ownership by 1% to 24,467 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/23/24 4:10:20 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Ryan Jason gifted 73,614 shares, closing all direct ownership in the company (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/12/24 4:31:01 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Saad Kareem sold $271 worth of shares (105 units at $2.58), decreasing direct ownership by 0.43% to 24,114 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/4/24 5:03:07 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

      STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial

      8/26/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Announces Chief Financial Officer Transition Plan

      Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo

      6/14/22 4:30:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology